7465800

7 known cases. View patent page →

Cases: 7
Active: 1; 6 closed
Filed: 2010–2018
Top venue: D. New Jersey; 6 cases

Filing activity

Cases asserting US Patent 7465800 filed per year.

Celgene Corporation v. Zydus Pharmaceuticals (USA) Inc. et al.

settled

Docket:: 2:17-cv-02528
Court:: U.S. District Court for the District of New Jersey
Filed:: 2017-04-12
Terminated:: 2021-03-24

Patents:8648095 7465800 7855217 7968569 8530498 9101621 9101622

π Celgene Corporation Δ Zydus Pharmaceuticals (USA) Inc.Δ Cadila Healthcare Ltd.Δ Zydus International Pvt. Ltd.

Celgene sued Zydus/Cadila/Zydus International for patent infringement under 35 U.S.C. § 271(e)(2) in D.N.J. The case asserted multiple lenalidomide patents including 8,648,095. Consent judgment entered 2021-03-24 dismissing with prejudice pursuant to settlement.

Celgene Corporation v. Dr. Reddy's Laboratories, Ltd. et al.

settled

Docket:: 2:16-cv-07704
Court:: U.S. District Court for the District of New Jersey
Filed:: 2016-10-20
Terminated:: 2020-09-17

Patents:7968569 7465800 7855217 8530498 8648095 9101621 9101622

π Celgene Corporation Δ Dr. Reddy's Laboratories, Ltd.Δ Dr. Reddy's Laboratories, Inc.

Patent infringement action involving ANDA No. 209348; complaint expressly alleged infringement of the '800, '217, '569, '498, '095, '621 and '622 patents. Settled September 17, 2020 with volume-limited license from September 1, 2022 and unlimited from January 31, 2026.

Celgene Corporation v. Sun Pharmaceutical Industries, Inc.

Docket:: 2:18-cv-11630
Court:: U.S. District Court for the District of New Jersey
Filed:: 2018-07-13

Patents:7968569 7465800 7855217

π Celgene Corporation Δ Sun Pharmaceutical Industries, Inc.

Patent infringement action against Sun Pharmaceutical. DrugPatentWatch lists patents-in-suit as 7,465,800; 7,855,217; 7,968,569. Judge Susan D. Wigenton presided.

In re Revlimid & Thalomid Purchaser Antitrust Litigation

active

Docket:: 2:19-cv-07532
Court:: U.S. District Court for the District of New Jersey

Patents:7968569 7465800 7855217 8315886 8404717 8530498 8648095 9056120 9101621 9101622

Δ Celgene Corporation

Antitrust/pay-for-delay litigation challenging Revlimid generic settlements. Patents cited include the Revlimid patent family; on September 29, 2026, the court denied motions to dismiss, finding a plausible pay-for-delay agreement between Celgene and Natco.

The Cigna Group v. Celgene Corporation

Court:: U.S. District Court for the District of New Jersey

Patents:7968569 7465800 7855217 8315886 8404717 8530498 8648095 9056120 9101621 9101622

π The Cigna Group Δ Celgene Corporation

Antitrust action against Celgene concerning Revlimid settlements; patents cited include the same Revlimid patent set as the In re Revlimid litigation.

Blue Cross Blue Shield Association plaintiffs v. Celgene Corporation et al.

Court:: U.S. District Court for the District of New Jersey

Patents:7968569 7465800 7855217 8315886 8404717 8530498 8648095 9056120 9101621 9101622

π Blue Cross Blue Shield Association plaintiffs Δ Celgene Corporation Δ Bristol-Myers Squibb

Antitrust action by Blue Cross Blue Shield Association plaintiffs against Celgene/BMS concerning Revlimid settlements; patents cited include the same Revlimid patent set as the In re Revlimid litigation.

Celgene Corporation v. Natco Pharma Limited et al.

settled; consent judgment entered

Docket:: 2:10-cv-05197 (SDW)(LDW); consolidated with 2:12-cv-04571 (SDW)(LDW)
Court:: U.S. District Court, District of New Jersey (Newark)
Filed:: 2010-10-08
Terminated:: 2016-01-05

Patents:6555554 5635517 6045501 6315720 6561976 6561977 6755784 7119106 7465800 6281230 8288415

π Celgene Corporation Δ Natco Pharma Limited Δ Arrow International Limited Δ Watson Laboratories, Inc.

Celgene asserted multiple patents, including the '554 patent, against Natco's lenalidomide ANDA No. 201452. The '554 claims were dismissed without prejudice by stipulation on March 26, 2015; the overall case settled with a consent judgment entered January 4, 2016, and terminated January 5, 2016.